Comparison of efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma.

ABSTRACT:

Purpose

This research aimed to compare the efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma.

Materials and methods

Patients with esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy plus albumin-bound paclitaxel and platinum-based chemotherapy followed by esophagectomy from December 2020 to May 2024 were retrospectively analyzed. The therapeutic efficacy, adverse reactions, and postoperative complications between the two- and three-cycle groups were analyzed using chi-square test and independent sample t-test. The overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method with log-rank test.

Results

A total of 138 esophageal sq

SUBMITTER: Ye G 

PROVIDER: S-EPMC12535011 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature